Table 1. HSPC products administered... | American Society of Hematology

Table 1.

HSPC products administered during myeloablative SCT

	Apheresis yield: CD34⁺ cells	Transduction efficiency, %	Injected cell dose, ×10⁶/kg	Days to neutrophil engraftment
DEFM	2.4 × 10⁷ Purity, 98.7% Viability, 100%	GFP, 42 YFP, 39	1.25 OIB 1.25 IV	7
DFRM	2.2 × 10⁷ Purity, 97.2% Viability, 100%	GFP, 45 YFP, 37	1.1 OIB 1.1 IV	10
ZL45	3.8 × 10⁷ Purity, 98.7% Viability, 100%	GFP, 42 YFP, 35	0.5 OIB 0.5 IV	15

	Apheresis yield: CD34⁺ cells	Transduction efficiency, %	Injected cell dose, ×10⁶/kg	Days to neutrophil engraftment
DEFM	2.4 × 10⁷ Purity, 98.7% Viability, 100%	GFP, 42 YFP, 39	1.25 OIB 1.25 IV	7
DFRM	2.2 × 10⁷ Purity, 97.2% Viability, 100%	GFP, 45 YFP, 37	1.1 OIB 1.1 IV	10
ZL45	3.8 × 10⁷ Purity, 98.7% Viability, 100%	GFP, 42 YFP, 35	0.5 OIB 0.5 IV	15

G-CSF and plerixafor-mobilized stem cells were collected from RMs via apheresis prior to immunomagnetic CD34⁺ selection in 3 separate experiments. The sample was then split equally and transduced with lentiviral vector encoding the reporters GFP or YFP.

SCT, stem cell transplantation.

View Large

This Feature Is Available To Subscribers Only